ð US FDA Approves Tylenol with Naproxen – First Nonprescription Fixed-Dose Combination for 12-Hour Pain Relief ð
The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen, the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for up to 12 hours of pain relief. The approval introduces a new over-the-counter (OTC) option for consumers seeking long-lasting, dual-action pain management without a prescription. ð
ð Drug Composition & Dosage
- ð Each Tablet Contains: 325 mg of acetaminophen and 110 mg of naproxen sodium
- â° Recommended Adult Dose: Two tablets every 12 hours
- ð Per Dose Delivery: 650 mg of acetaminophen + 220 mg of naproxen sodium
- ðĨ Approved For: Adults and children aged 12 years and older
ðŊ Approved Indications
It is approved for the temporary relief of:
- ðĪ Headache
- ðĶī Backache & Muscular aches
- ðĶ· Toothache
- ðĐļ Menstrual cramps
- ðĶĩ Minor arthritis pain
- ðŠ Other minor aches and pains
ð First-of-its-Kind Approval
According to the FDA, while several OTC medicines combine acetaminophen with other nonsteroidal anti-inflammatory drugs (NSAIDs), this is the first product to combine acetaminophen with naproxen sodium in a single nonprescription tablet. The approval was supported by evidence demonstrating the safety and effectiveness of the combination and the contribution of each ingredient to pain relief. â
ð Manufacturer Details
ðĒ The product is manufactured by Kenvue Brands LLC, the company behind the Tylenol brand. Kenvue states that the dual-action formulation begins working in under 30 minutes and provides pain relief for up to 12 hours, potentially reducing the need for multiple doses throughout the day. âĄ
â ïļ Important FDA Warnings & Safety Information
The FDA emphasized that consumers should carefully follow the product labeling:
- ðŦ Acetaminophen Warning: Should not be used with other acetaminophen-containing products due to risk of liver damage
- â ïļ NSAID Warning: Label includes warnings regarding stomach bleeding
- âĪïļ Cardiovascular Risk: Increased risk of heart attack, heart failure, and stroke, particularly when used at higher doses or longer than recommended
- ðĪ° Pregnancy: Pregnant or breastfeeding individuals should consult healthcare professional before use, and naproxen sodium should generally be avoided after 20 weeks of pregnancy unless directed by physician
ðĄ Significance:
The approval expands the range of available nonprescription pain relief options and offers consumers a convenient fixed-dose combination that targets pain through two different mechanisms of action in a single tablet. ðâĻ
